3 months ago
- Intelligence alone is often not the main bottleneck in the real world; regulation and governance are key constraints.
- In medicine, clinical trials consume seven years and over a billion dollars per drug, slowing progress despite AI advances.
- Biomedical innovation is hindered by factors like target herding and patent systems that disincentivize novel biology.
- Diffusion of technology is slow and uneven; capabilities do not automatically translate into real-world outcomes.
- San Francisco's tech monoculture overestimates AI's transformative power, dismissing non-technical bottlenecks.
- Mistaken beliefs about AI lead to misallocated priorities, neglecting mundane but pressing societal problems.